U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283692) titled 'Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)' on Dec. 04.
Brief Summary: This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Triple Negative Breast Cancer
Intervention:
DRUG: Serplulimab
1.5mg/kg qw, start from C1D15
DRUG: Paclitaxel
80mg/m^2 qw
DRUG: Carboplatin
AUC=1.5, D1, 8, 15, every 28 days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: RenJi Hospital
Inform...